WallStreetZenWallStreetZen

NASDAQ: STIM
Neuronetics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their STIM stock forecasts and price targets.

Forecast return on equity

Is STIM forecast to generate an efficient return?

Company
N/A
Industry
-177.45%
Market
180.15%

Forecast return on assets

Is STIM forecast to generate an efficient return on assets?

Company
N/A
Industry
16.4%

STIM earnings per share forecast

What is STIM's earnings per share in the next 2 years based on estimates from 5 analysts?

Avg 1 year Forecast
-$0.47
Avg 2 year Forecast
-$0.33

STIM revenue forecast

What is STIM's revenue in the next 3 years based on estimates from 5 analysts?

Avg 1 year Forecast
$167.5M+28.93%
Avg 2 year Forecast
$188.0M+44.75%
Avg 3 year Forecast
$216.2M+66.5%
STIM's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

STIM revenue growth forecast

How is STIM forecast to perform vs Diagnostics & Research companies and vs the US market?

Company
18.17%
Industry
8.52%
Market
13.47%
STIM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
STIM's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

STIM vs Diagnostic & Research Stocks

TickerPricePrice TargetUp/downsideConsensus
STIM$1.41N/AN/A
SERA$2.00N/AN/A
XGN$3.22$11.60+260.25%Strong Buy
FONR$18.57N/AN/A
DRIO$9.99N/AN/A
View Top Diagnostic & Research Stocks

Neuronetics Stock Forecast FAQ

What is STIM's earnings growth forecast for 2026-2027?

(NASDAQ: STIM) Neuronetics's forecast annual earnings growth rate of N/A is not forecast to beat the US Diagnostics & Research industry's average forecast earnings growth rate of 18.04%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 36.32%.

Neuronetics's earnings in 2026 is -$44,502,000.On average, 5 Wall Street analysts forecast STIM's earnings for 2026 to be -$32,133,595, with the lowest STIM earnings forecast at -$32,886,940, and the highest STIM earnings forecast at -$30,921,394.

In 2027, STIM is forecast to generate -$22,819,509 in earnings, with the lowest earnings forecast at -$22,148,347 and the highest earnings forecast at -$23,011,270.

If you're new to stock investing, here's how to buy Neuronetics stock.

What is STIM's revenue growth forecast for 2026-2028?

(NASDAQ: STIM) Neuronetics's forecast annual revenue growth rate of 18.17% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.52%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.47%.

Neuronetics's revenue in 2026 is $129,873,000.On average, 5 Wall Street analysts forecast STIM's revenue for 2026 to be $11,467,967,639, with the lowest STIM revenue forecast at $10,993,360,199, and the highest STIM revenue forecast at $11,843,955,351. On average, 5 Wall Street analysts forecast STIM's revenue for 2027 to be $12,874,668,477, with the lowest STIM revenue forecast at $12,107,626,150, and the highest STIM revenue forecast at $13,483,508,323.

In 2028, STIM is forecast to generate $14,809,395,773 in revenue, with the lowest revenue forecast at $14,228,635,155 and the highest revenue forecast at $15,244,966,237.

What is STIM's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: STIM) forecast ROA is N/A, which is lower than the forecast US Diagnostics & Research industry average of 16.4%.

What is STIM's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: STIM) Neuronetics's current Earnings Per Share (EPS) is -$0.83. On average, analysts forecast that STIM's EPS will be -$0.47 for 2026, with the lowest EPS forecast at -$0.48, and the highest EPS forecast at -$0.45. In 2027, STIM's EPS is forecast to hit -$0.33 (min: -$0.32, max: -$0.34).

What is STIM's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: STIM) forecast ROE is N/A, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.